ARTICLE
INFLAMMATION, EXTRACELLULAR MEDIATORS AND EFFECTOR MOLECULES

The anti-inflammatory peptide Catestatin blocks chemotaxis

Elke M. Muntjewerff1 | Kristel Parv2 | Sushil K. Mahata3,4 | N. Koen van Riessen1 | Mia Phillipson2,5 | Gustaf Christoffersson2,5 | Geert van den Bogaart1,6

1 Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
2 Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden
3 VA San Diego Healthcare System, University of California San Diego, La Jolla, California, USA
4 Department of Medicine, University of California San Diego, La Jolla, California, USA
5 Science for Life Laboratory, Uppsala University, Uppsala, Sweden
6 Department of Molecular Immunology and Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, the Netherlands

Correspondence
Geert van den Bogaart, Department of Molecular Immunology and Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen the Netherlands.
Email: g.van.den.bogaart@rug.nl
Gustaf Christoffersson, Department of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Email: gustaf.christoffersson@scilifelab.uu.se

Abstract
Increased levels of the anti-inflammatory peptide Catestatin (CST), a cleavage product of the pro-hormone chromogranin A, correlate with less severe outcomes in hypertension, colitis, and diabetes. However, it is unknown how CST reduces the infiltration of monocytes and macrophages (MΦs) in inflamed tissues. Here, it is reported that CST blocks leukocyte migration toward inflammatory chemokines. By in vitro and in vivo migration assays, it is shown that although CST itself is chemotactic, it blocks migration of monocytes and neutrophils to inflammatory attracting factor CC-chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 2 (CXCL2). Moreover, it directs CX3CR1+ MΦs away from pancreatic islets. These findings suggest that the anti-inflammatory actions of CST are partly caused by its regulation of chemotaxis.

KEYWORDS
catestatin, chemotaxis, MΦs, migration, monocytes, neutrophil, pro-angiogenesis

1 INTRODUCTION

As an immunological response to inflammation, leukocytes are attracted to inflamed tissues by chemokines such as CC-chemokine ligand 2 (CCL2, a.k.a. MCP-1) and C-X-C motif chemokine ligand 2 (CXCL2, a.k.a. MIP-2).1 However, to avoid an excessive response, leukocyte infiltration should be halted for the resolution of inflammation, but not all the mechanisms that govern this are known.2 Here, we addressed the potential chemotactic effect of the chromogranin A (CgA)-derived peptide catestatin (CST; hCgA352-372).3,4 CgA and its bioactive peptide CST are produced by endocrine cells, for example, chromaffin and pancreatic beta cells, and bone-marrow-derived cells such as macrophages (MΦs).5–7 While the concentrations of CST in circulation are in the low nM range, concentrations in the µM range were detected in mouse tissues.3,8–10 These much higher concentrations indicate that CST exerts its effects locally. CST has primarily anti-inflammatory properties, as CST reduces inflammation in cardiac and chronic inflammatory diseases and CST-knockout mice display increased inflammation in the intestine, heart, and adrenal gland.7,8,11,12 However, CST has also pro-inflammatory effects as it

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. Journal of Leukocyte Biology published by Wiley Periodicals LLC on behalf of Society for Leukocyte Biology.
**FIGURE 1** CST is weakly chemotactic. (A) Scheme showing set-up of Gradientech migration assay. Two syringes filled with buffer ± chemoattractant were connected to the device (green) to create a flow (y-direction) and perpendicular (x) cytokine gradient. The inset shows the migration of monocytes along with the flow and towards the chemoattractant. (B) Representative tracks of human monocytes showing the x- and y-movement of individual cells upon exposure to the indicated buffer, 5 µM CST or 0.5 nM CCL2. (C) Quantification of panel B (N = 3). (D) Scheme showing set-up of cremaster muscle imaging in mice to visualize phagocyte (monocytes and neutrophils) extravasation in vivo. (E) Phagocyte rolling velocity (top) and attachment (bottom) upon overflowing the muscle with buffer (control, gray), 0.5 nM MIP-2 (blue) or 5 µM CST (black) for 90 minutes (imaged at T = 0, 30, 60, 90) (N = 3, two-way ANOVA). (F) Representative images of granulocyte attachment over time (imaged at T = 0, 30, 60, 90 minutes) to the vessel wall upon only buffer, CXCL2, or CST stimulation as visualized with an antibody against Ly6G (green). *P < 0.05; **P < 0.01; ***P < 0.001; ns: not significant
is chemotactic and promotes the production of inflammatory chemokines (IL-8, CCL2-4). Nevertheless, administration of exogenous CST reduces monocyte and Mφ infiltration in the liver, heart, and gut in mouse models of type II diabetes, hypertension, atherosclerosis, and colitis. In a colitis model, CST also reduced granulocyte infiltration in the colon. Finally, the adrenal gland, heart, and gut of CST knockout mice display increased Mφ infiltration. These findings raise the question of how CST affects leukocyte chemotaxis.

In this study, we show that while CST itself is chemotactic, it blocks the extravasation and migration of phagocytes both in vitro and in vivo. These findings support a model where the anti-inflammatory effects of CST could be partly the result of redirecting monocytes and neutrophils away from the inflammation sites.

## RESULTS & DISCUSSION

Transwell migration assays on human blood monocytes showed only a weak chemotactic effect of CST in a broad concentration range (1 nM–5 µM) (Supplementary Fig. S1). In line with this, human blood monocytes migrated towards a high concentration of CST (5 µM) in the gradientech assay, but this migration was not significant and less efficient compared to the canonical inflammatory chemokine CCL2 (0.5 nM) (Fig. 1A-C). To investigate the effect of CST on phagocytes in vivo, we performed imaging of the mouse cremaster muscle to follow the rolling of monocytes (unstained) and neutrophils (Ly6G+ stained cells) using intravenous injection of fluorescently labeled antibody against Ly6G (Fig. 1D). Upon superfusion of the muscle with CST (5 µM),...
FIGURE 3  CST blocks migration induced by inflammatory cytokines. (A) Cremaster muscle imaging. Phagocyte attachment to vessel wall upon overflowing the muscle with buffer (control, gray) and buffer with the chemoattractant CXCL2 (blue), CST (black), or both (red) (N = 3, two-way ANOVA). (B) Representative images of granulocyte and monocyte attachment at T = 90 min to the vessel wall upon only buffer, CXCL2, CST, or stimulation with both, as visualized with antibodies against Ly6G (green) and CD115 (red). (C) Monocyte (upper) and granulocyte (lower) attachment to vessel wall upon overflowing the muscle with buffer (control, gray) and buffer with the chemoattractant CXCL2 (blue), CST (black), or both (red). (D) Representative hematoxylin-eosin (HE) images of mouse phagocyte migration in transwell assay toward IL-8, CST, or both. (E) Graphs displaying migrated mouse neutrophils (left) and monocytes (right) toward the lower compartment of the transwell assay filled with only medium or medium containing IL-8, CST, or both. (F) Percentages of migrated human monocytes toward the lower compartment of the transwell assay filled with only medium or medium containing CCL2, CST, or both. (G) Gradientech migration assay. Representative x- and y-movement of human monocytes exposed to opposite gradients of CST and CCL2 (N = 3). Mann-Whitney test *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns: not significant.

Both monocytes and neutrophils decreased their speed and attached to the vessel wall with similar efficiency as with the inflammatory chemoattractant CXCL2 (0.5 nM) (Fig. 1D-F; Supplementary Fig. S2A-D). Thus, both our in vivo and in vitro migration assays support that CST is chemotactic, although the effects in vivo in mice are stronger than for human monocytes in vitro. Possibly, the local surroundings in the tissues (e.g., epithelial cells or cytokines) enhance the chemotactic effect of CST in vivo. These findings raise the question of how CST can reduce the reported monocyte and granulocyte infiltration in inflamed tissues such as the liver (in diet-induced obese mice), intestine (in colitis model), heart (in hypertension model), and atheromatous plaques (in atherosclerosis model) 

7,8,11,12,15

To address how CST affects Mϕ chemotaxis to inflamed tissues, we used the aortic ring vessel model 17 (Fig. 2A), which is based on the...
co-embedding of part of the aorta of Cx3CR1-gfp transgenic mice adjacent to isolated pancreatic islets.\textsuperscript{18} These islets secrete chemokines, such as vascular endothelial growth factor (VEGF)-A, resulting in the directional Mφ migration from the aortic ring as well as vessel growth towards the pancreatic islets. Migration of Cx3CR1\textsuperscript{+/+} Mφs from the aortic ring was visualized by fluorescence microscopy\textsuperscript{19} (Fig. 2B-C; Supplementary Fig. S3). As expected, the Cx3CR1-Mφs moved toward the pancreatic islets in absence of CST (Figure 2B). However, perfusing the aortic ring with CST (5 μM) resulted in a lower number of Cx3CR1\textsuperscript{+/+} Mφs migrating toward the pancreatic islets (Figure 2B), indicating that CST blocked directional migration. Interestingly, we also observed that CST is pro-angiogenic, as it increased both the amount and length of the sprouts and branches emanating from the aortic rings (Fig. 2C-D; Fig. S4).

The loss of directional cell migration to the pancreatic islets might be caused by blockage of chemokine-induced cell migration by CST. To investigate this possibility, we performed intravital imaging of the cremaster muscle, but this time for CST in combination with CXCL2. This resulted in the inverse effect compared to CST or CXCL2 alone: release of attached cells from the vessel wall and reduced migration of cells into the tissue (Fig. 3A; Supplementary Fig. S5A-C), indicating that despite being chemotactic, CST blocks CXCL2 elicited phagocyte recruitment. To confirm that CST exerts this effect on both monocytes and neutrophils, we performed intravital imaging of the cremaster muscle with intravenous injection of CD115\textsuperscript{+} antibody to stain monocytes and Ly6G\textsuperscript{+} antibody to stain neutrophils. Again, the combination of CST and CXCL2 resulted in less recruitment of both monocytes (CD115\textsuperscript{+}) and neutrophils (Ly6G\textsuperscript{+}) compared to CST or CXCL2 alone (Fig. 3B-C).

To test if CST could also block chemotaxis to other chemokines, we performed in vitro transwell migration assays with both human and mouse phagocytes (Fig. 3; Supplementary Fig. S6). While IL-8 alone attracted mouse neutrophils as expected,\textsuperscript{20} IL-8 in combination with CST blocked the neutrophil migration to the lower compartment of the transwell (Fig. 3D and E). The combination of IL-8 and CST did not affect the migration of human monocytes (Supplementary Fig. S6D). CST did not block migration of mouse phagocytes and human monocytes towards the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP) (Supplementary Fig. S6A-C).

Another factor that can influence immune cell migration is their exposure to microbial agents, such as lipopolysaccharide (LPS), which induce their activation.\textsuperscript{21} To determine whether pre-treatment of the cells with LPS or CST can influence the blocking effect of CST, we pre-stimulated human monocytes 30 minutes with LPS or CST before performing the in vitro transwell migration assays (Supplementary Fig. S7). Again, we observed that CST could block CCL2-induced monocyte migration, and, although not significant, this effect did not seem altered by pretreatment of the cells with LPS or CST (Fig. 3F; Supplementary Fig. S7B). To confirm the observed block of chemotaxis in human monocytes by CST, we performed an in vitro gradient-chamber migration assay with a gradient of CCL2 in presence of CST (Fig. 3G). Similar to our findings with the intravital imaging, CST blocked monocyte migration toward CCL2.

Our findings indicate that CST counteracts the chemoattraction of leukocytes by inflammatory chemokines CCL2, CXCL2, and IL-8. This could contribute to the previously observed reduced immune infiltrate in the liver, heart, and gut in mouse models of type II diabetes, hypertension, atherosclerosis, and colitis upon treatment with CST.\textsuperscript{7,8,11,12,15} However, CST has been reported to promote the production of chemokines\textsuperscript{14} and we confirmed previous findings that CST is chemotactic itself,\textsuperscript{11,13,14} indicating that the regulation of chemotaxis by CST is complex. To understand this regulation, the receptor(s) for CST needs to be identified. We speculate that this might be a G-protein coupled receptor (GPCR), since GPCRs are actively involved in leukocyte migration\textsuperscript{22} and are widely expressed in all cell types responsive to CST (e.g., monocytes,\textsuperscript{15} neutrophils,\textsuperscript{23,24} Mφs,\textsuperscript{7,8,11,12,15} endothelial,\textsuperscript{12,25} and mast cells).\textsuperscript{14} Moreover, CCL2, CXCL2, and IL-8 all signal via GPCRs.\textsuperscript{26} Possibly, CST treatment causes a heterologous desensitization to these chemotaxins.

Another open question is how the chemotactic properties of CST are regulated in vivo. CgA, the precursor of CST, is co-released with catecholamines by neuroendocrine cells,\textsuperscript{4,27–29} suggesting that these cells might prevent or limit immune cell infiltration in an activity-based fashion. However, neutrophils and Mφs also produce CST themselves,\textsuperscript{7,23,30,31} arguing that CST might downregulate their infiltration in an autocrine fashion.

In any case, our data suggest that CST reduces the infiltration of monocytes and Mφs in inflamed tissues,\textsuperscript{7,8,11,12,15} offering a possible mechanistic explanation for the correlation of CST levels with improved disease outcome in patients suffering from chronic diseases.\textsuperscript{8–11,32} These findings reinforce the emerging concept that CST could be a therapeutic target for the treatment of diseases associated with chronic inflammation.\textsuperscript{5,7,8,11,33}

**AUTHORSHIP**

E.M.M., G.C., S.K.M., and G.v.d.B. designed the study. E.M.M, K.P., and G.C. designed and performed the experiments. N.K.R. contributed to the in vitro mice experiments. E.M.M. and G.v.d.B wrote the manuscript and all authors (E.M.M., K.P., G.C., M.P., S.K.M., and G.v.d.B) participated in discussing and editing the manuscript.

**DISCLOSURE**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**FUNDING**

G.v.d.B. is funded by a Young Investigator Grant from the Human Frontier Science Program (HFSP; RGY0080/2018), and a Vidi grant from the Netherlands Organization for Scientific Research (NWO-ALW VIDI 864.14.001). G.v.d.B. has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No. 862137). S.K.M. is supported
by a grant from the US Department of Veterans Affairs (I01BX000323). G.C. is supported by grants from the Swedish Research Council, the Swedish Society for Medical Research, and the Göran Gustafsson foundation. E.M.M. is supported by a short-term EMBO fellowship (EMBO7887).

DATA AND MATERIALS AVAILABILITY

All data in the main text or the supplementary materials are available. Raw data is available upon request via Geert van den Bogaart (gvan.den.bogaart@rug.nl) and Gustaf Christoffersson (gustaf.christoffersson@scilifelab.uu.se).

REFERENCES

1. Deshmule SL, Kremlev S, Amini S, Sawaya BE. Review Monocyte Chemotactant Protein-1 (MCP-1): An Overview. https://doi.org/10.1089/jlr.2008.0027
2. Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of inflammation: what controls its onset?. Front Immunol. 2016;7.
3. Muntjewerff EM, Dunkel G, Nicolaes MJT, Mahata SK, Van Den Bogaart G. Catestatin as a target for treatment of inflammatory diseases. Front Immunol. 2018;9:2199.
4. Mahata SK, O’Connor DT, Mahata M, et al. Novel autocrine feed-back control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest. 1997;100:1623-1633.
5. Montero-Hadjadje M, Vaingankar S, Elias S, Tostivint H, Mahata SK, Anouar Y. Chromogranins A and B and secretogranin II: Evolutionary and functional aspects. Acta Physiol. 2008;192:309-324.
6. Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP, Salton SRJ. The extended granin family: structure, function, and biomedical implications. Endocr Rev. 2011;32:755-797.
7. Ying W, Tang K, Avolio E, et al. Immunosuppression of macrophages underlies the cardioprotective effects of CST (Catestatin). Hypertension. 2021;77:1670-1682.
8. Muntjewerff EM, Tang K, Lutter L, et al. Chromogranin A regulates gut permeability via the antagonistic actions of its proteolytic peptides. Acta Physiol. 2021;232:e13653.
9. Živkovic PM, Mateić A, Tadin Hadijina I, et al. Serum catestatin levels and arterial stiffness parameters are increased in patients with inflammatory bowel disease. J Clin Med. 2020;9:628.
10. Corti A, Marcacci F, Bachechi T. Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers. Pflügers Arch - Eur J Physiol. 2017;470:199-210.
11. Ying W, Mahata S, Bandyopadhyay GK, et al. Catestatin inhibits obesity-induced macrophage infiltration and inflammation in the liver and suppresses hepatic glucose production, leading to improved insulin sensitivity. Diabetes. 2018;67:941-948.
12. Kojima M, Ozawa N, Mori Y, et al. Catestatin prevents macrophage-driven atherosclerosis but not arterial injury-induced neointimal hyperplasia. Thromb Haemost. 2018;118:182-194.
13. Egger M, Beer AGE, Theurl M, et al. Monocyte migration: a novel effect and signaling pathways of catestatin. Eur J Pharmacol. 2008;598:104-111.
14. Aung G, Niyonsaba F, Ushio H, et al. Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines. Immunology. 2011;132:527-539.
15. Rabbit MF, Labs B, Metz-Boutigue MH, Bernstein CN, Ghia J-E. Catestatin decreases macrophage function in two mouse models of experimental colitis. Biochem Pharmacol. 2014;89:386-398.
16. Mahapatra NR, O’Connor DT, Vaingankar SM, et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest. 2005;115:1942-1952.
17. Baker M, Robinson SD, Lechtert T, et al. Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc. 2012;7:89-104.
18. Nicosia RF, Gelati M, Aplin AC, Fogel E, Smith KD. Macrophages requires injury and inflammatory cytokines the angiogenic response of the aorta to. J Immunol Ref. 2008;181:5711-5719.
19. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676-682.
20. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol. 1994;56:559-564.
21. Wilde CG, Seilhamer JJ, McGroghan M, et al. Bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein. LPS binding properties and effects on LPS-mediated cell activation. J Biol Chem. 1994;269:17411-17416.
22. Lämmermann T, Kastenmüller W. Concepts of GPCR-controlled navigation in the immune system. Immunol Rev. 2019;289:205-231.
23. Zhang D, Shooshatarizadeh P, Laventie BJ, et al. Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2. PLoS One. 2009;4:e4501.
24. Briolat J, Wu SD, Mahata SK, et al. New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. Cell Mol Life Sci. 2005;62:377-385.
25. Theurl M, Schgoer W, Albrecht K, et al. The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ Res. 2010;107:1326-1335.
26. Sun L, Ye RD. Role of G protein-coupled receptors in inflammation. Acta Pharmacol Sin. 2012;33:342-350.
27. Mahata SK, Mahata M, Fung MM, O’Connor DT. Catestatin: a multifunctional peptide from chromogranin A. Regul Pept. 2010;162:33-43.
28. Sahu BS, Mahata S, Bandyopadhyay K, et al. Catestatin regulates vesicular quanta through modulation of cholinergic and peptidergic (PACA-Pergic) stimulation in PC12 cells. Cell Tissue Res. 2019;376:51-70.
29. Takiyyuddin MA, Cervenka JH, Sullivan PA, et al. Is physiologic sympathoadrenal catecholamine release exocytotic in humans?. Circulation. 1990;81:185-195.
30. Muntjewerff EM, Lutter L, Tang K, et al. Catestatin regulates the colonic mucus layer in inflammatory bowel disease. (2021) https://doi.org/10.1101/2021.02.09.430377
31. Briolat J, Wu SD, Mahata SK, et al. New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. C Cell Mol Life Sci. 2005;62:377-385.
32. O’Connor DT, Zhu G, Rao F, et al. Heritability and genome-wide linkage in us and australian twins identify novel genomic regions controlling the aorta to. J Immunol Ref. 2008;115:1942-1952.
33. Mahata SK, Corti A. Chromogranin a and its fragments in cardiovascular, immunometabolic, and cancer regulation. Ann N Y Acad Sci. 2019;1455:34-58.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Muntjewerff EM, Parv K, Mahata SK, et al. The anti-inflammatory peptide Catestatin blocks chemotaxis. J Leukoc Biol. 2022;112:273–278. https://doi.org/10.1002/JLB.3CRA1220-790RR